Mealey's (February 15, 2018, 1:33 PM EST) -- BOSTON — A group of investors may aggregate their losses and has met all statutory requirements to serve as lead plaintiff in a securities class action lawsuit against a biopharmaceutical company and two of its senior officers over misrepresentations that they made regarding the company’s prospects for its herpes treatment, a federal judge in Massachusetts ruled Feb. 12 in granting the investor group’s motion for appointment as lead plaintiff (Steven Emerson, et al. v. Genocea Biosciences Inc., et al., No. 17-12137, D. Mass., 2018 U.S. Dist. LEXIS 22228)....